Melanogenesis detection method using FAM86A

A method of treating a melanin-deficient disease in a subject, comprising administering a pharmaceutically effective amount of composition comprising an FAM86A inhibitor as an active ingredient into the subject,

• wherein the FAM86A inhibitor is an FAM86A expression inhibitor,
• wherein the FAM86A expression inhibitor is an shRNA that complementarily binds to a mRNA of the FAM86A gene, and
• wherein the melanin-deficient disease is selected from the group consisting of:
• leukoderma;
• vitiligo;
• quadrichrome vitiligo;
• vitiligo ponctue;
• syndromic albinism;
• Alezzandrini syndrome;
• Hermansky-Pudlak syndrome;
• Chediak-Higashi syndrome;
• Griscelli syndrome type 1/Elejalde syndrome;
• Griscelli syndrome type 2;
• Griscelli syndrome type 3;
• Waardenburg syndrome;
• Tietz syndrome;
• CrossMuKusick-Breen syndrome;
• ABCD syndrome;
• Albinism-deafness syndrome;
• Vogt-Koyanagi-Harada syndrome;
• oculocutaneous albinism;
• canities;
• hypomelanosis;
• idiopathic guttate hypomelanosis;
• phylloid hypomelanosis;
• progressive macular hypomelanosis;
• piebaldism;
• nevus depigmentosus;
• postinflammatory hypopigmentation;
• pityriasis alba;
• Vagabond's leukomelanoderma;
• Yemenite deaf-blind hypopigmentation syndrome;
• Wende-Bauckus syndrome;
• Woronoff's ring;
• amelanism;
• and leucism.